Longitudinal pharmacometabonomics for predicting patient responses to therapy: Drug metabolism, toxicity and efficacy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 2, 2012, Pages 135-139

  Nicholson, Jeremy K ^a   Everett, Jeremy R ^b   Lindon, John C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

chemotherapy; diagnosis; drug metabolism; genomics; metabolomics; metabonomics; personalised health care; pharmacogenomics; pharmacometabonomics; prognosis; surgery; toxicity

Indexed keywords

CAPECITABINE; GALACTOSAMINE;

ALLELE; COLORECTAL CANCER; DISEASE COURSE; DRUG EFFICACY; DRUG METABOLISM; ENVIRONMENTAL FACTOR; HUMAN; INTESTINE FLORA; MEDICAL ETHICS; METAGENOMICS; MICROBIOME; NONHUMAN; NUTRITION; PATIENT MONITORING; PHARMACOGENOMICS; PHARMACOMETABONOMICS; REVIEW; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; DRUG THERAPY; DRUG TOXICITY; HUMANS; METABOLOMICS; PHARMACEUTICAL PREPARATIONS;

EID: 84856120472     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.646987     Document Type: Review

References (15)

1. Scheiber J. How can we enable drug discovery informatics for personalized healthcare. Expert Opin Drug Discov 2011;6:219-24
2. Yong WP, Innocenti F Ratain MJ. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 2006;62:35-46 (Pubitemid 44195241)
3. Watson RG, McLeod HL. Pharmacogenomic contribution to drug response. Cancer J 2011;17:80-8
4. Clayton TA, Lindon JC, Cloarec O, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006;440:1073-7
5. Clayton TA, Baker D, Lindon JC, et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 2009;106:14728-33
6. Winnike JH, Wright FA, Macdonald JM, et al. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharm 2010;88:45-51
7. Phapale PB, Kim SD, Lee HW, et al. An integrated approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clin Pharmacol Ther 2010;87:426-36
8. Kinross JM, Holmes E, Darzi AW, et al. Metabolic phenotyping in monitoring of surgical patients. Lancet 2011;377:1817-19
9. Nicholson G, Rantalainen M, Maher AD, et al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol 2011;7:525
10. Rezzi S, Ramadan Z, Martin F-PJ, et al. Human metabolic phenotypes link directly to specific dietary preferences in healthy individuals. J Proteome Res 2007;6:4469-77 (Pubitemid 350158522)
11. Jia W, Li H, Zhao L, et al. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov 2008;7:123-9 (Pubitemid 351194060)
12. Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010;330:831-5
13. Yap IKS, Angley M, Veselkov KA, et al. Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res 2010;9:2996-3004
14. Backshall A, Sharma R, Clarke SJ, et al. Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res 2011;17:3019-28
15. Lindon JC, Nicholson JK. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Ann Rev Anal Chem 2008;1:45-69